journal article·2022-05Open access

A Selective β−Catenin‐Metadherin/CEACAM1‐CCL3 Axis Mediates Metastatic Heterogeneity upon Tumor–Macrophage Interaction

Sally K. Y. To, Maggie K. S. Tang, Yin Tong, Jiangwen Zhang, Karen K. L. Chan, Philip P. C. Ip, Jue Shi, Alice S. T. Wong

Advanced Science· Volume 9· Issue 16

Abstract

Abstract Tumor heterogeneity plays a key role in cancer relapse and metastasis, however, the distinct cellular behaviors and kinetics of interactions among different cancer cell subclones and the tumor microenvironment are poorly understood. By profiling an isogenic model that resembles spontaneous human ovarian cancer metastasis with an highly metastatic (HM) and non‐metastatic (NM) tumor cell pair, one finds an upregulation of Wnt/β‐catenin signaling uniquely in HM. Using humanized immunocompetent mice, one shows for the first time that activated β‐catenin acts nonautonomously to modulate the immune microenvironment by enhancing infiltrating tumor‐associated macrophages (TAM) at the metastatic site. Single‐cell time‐lapse microscopy further reveals that upon contact with macrophages, a significant subset of HM, but not NM, becomes polyploid, a phenotype pivotal for tumor aggressiveness and therapy resistance. Moreover, HM, but not NM, polarizes macrophages to a TAM phenotype. Mechanistically, β‐catenin upregulates cancer cell surface metadherin, which communicates through CEACAM1 expressed on macrophages to produce CCL3. Tumor xenografts in humanized mice and clinical patient samples both corroborate the relevance of enhanced metastasis, TAM activation, and polyploidy in vivo. The results thus suggest that targeting the β‐catenin‐metadherin/CEACAM1‐CCL3 positive feedback cascade holds great therapeutic potential to disrupt polyploidization of the cancer subclones that drive metastasis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Mechanisms and Therapy · Peptidase Inhibition and Analysis · Cell Adhesion Molecules Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Biological Sciences The University of Hong Kong Pokfulam Road Hong Kong China

Laboratory for Synthetic Chemistry and Chemical Biology Limited 17W, Hong Kong Science and Technology Parks, New Territories Hong Kong China

Department of Pathology The University of Hong Kong Queen Mary Hospital Pokfulam Road Hong Kong

Department of Obstetrics & Gynaecology The University of Hong Kong Queen Mary Hospital Pokfulam Road Hong Kong China

Centre for Quantitative Systems Biology and Department of Physics Hong Kong Baptist University Hong Kong China

References (59)

Show source-provided references
1. 10.3322/caac.2165410.3322/caac.21654 ↗
2. 10.1038/nrc161110.1038/nrc1611 ↗
3. 10.2353/ajpath.2010.10010510.2353/ajpath.2010.100105 ↗
4. 10.1038/nrclinonc.2017.16610.1038/nrclinonc.2017.166 ↗
5. 10.1038/nrc326110.1038/nrc3261 ↗
6. 10.1038/nri252810.1038/nri2528 ↗
7. 10.1038/nrc125610.1038/nrc1256 ↗
8. 10.1038/nrclinonc.2016.21710.1038/nrclinonc.2016.217 ↗
9. 10.1007/s12026-009-8100-210.1007/s12026-009-8100-2 ↗
10. 10.1038/nrc343210.1038/nrc3432 ↗
11. 10.3390/cells905129910.3390/cells9051299 ↗
12. 10.1158/0008-5472.CAN-06-437510.1158/0008-5472.CAN-06-4375 ↗
13. 10.1038/onc.2017.18510.1038/onc.2017.185 ↗
14. 10.1038/nrc401910.1038/nrc4019 ↗
15. 10.1158/1078-0432.CCR-17-228310.1158/1078-0432.CCR-17-2283 ↗
16. 10.1038/s41467-018-06152-x10.1038/s41467-018-06152-x ↗
17. 10.4049/jimmunol.172.5.273110.4049/jimmunol.172.5.2731 ↗
18. 10.1007/978-1-60327-360-2_1310.1007/978-1-60327-360-2_13 ↗
19. Auwerx J. · Experientia · 2010 · 15 · 22
20. 10.1158/0008-5472.CAN-10-322310.1158/0008-5472.CAN-10-3223 ↗
21. 10.1073/pnas.171976011510.1073/pnas.1719760115 ↗
22. 10.3389/fonc.2014.0012310.3389/fonc.2014.00123 ↗
23. 10.1016/S1535-6108(04)00079-010.1016/S1535-6108(04)00079-0 ↗
24. 10.1016/B978-0-12-401676-7.00001-210.1016/B978-0-12-401676-7.00001-2 ↗
25. 10.1038/emboj.2012.15010.1038/emboj.2012.150 ↗
26. 10.1038/nrd423310.1038/nrd4233 ↗
27. 10.1038/nri186410.1038/nri1864 ↗
28. 10.1074/jbc.M10813520010.1074/jbc.M108135200 ↗
29. Milliken D. · Clin. Cancer Res. · 2002 · 8 · 1108
30. Matte I. · Am. J. Cancer Res. · 2012 · 2 · 566
31. 10.4049/jimmunol.181.9.638410.4049/jimmunol.181.9.6384 ↗
32. 10.1042/bsr2020117510.1042/bsr20201175 ↗
33. 10.3892/or.18.5.110710.3892/or.18.5.1107 ↗
34. 10.1007/978-3-030-36667-4_210.1007/978-3-030-36667-4_2 ↗
35. 10.1084/jem.2014183610.1084/jem.20141836 ↗
36. 10.1126/science.122492210.1126/science.1224922 ↗
37. 10.1038/nrm127610.1038/nrm1276 ↗
38. 10.1016/j.semcancer.2020.11.01610.1016/j.semcancer.2020.11.016 ↗
39. 10.1158/2159-8290.CD-13-028510.1158/2159-8290.CD-13-0285 ↗
40. 10.1158/1535-7163.MCT-15-052710.1158/1535-7163.MCT-15-0527 ↗
41. 10.1073/pnas.131844011110.1073/pnas.1318440111 ↗
42. 10.1158/1541-7786.MCR-13-017210.1158/1541-7786.MCR-13-0172 ↗
43. 10.1016/j.molonc.2013.12.01410.1016/j.molonc.2013.12.014 ↗
44. 10.2174/138945011100701134110.2174/1389450111007011341 ↗
45. 10.1038/ncb304110.1038/ncb3041 ↗
46. 10.1172/JCI8725210.1172/JCI87252 ↗
47. 10.3389/fonc.2019.0034910.3389/fonc.2019.00349 ↗
48. 10.1111/j.1365-2559.2012.04182.x10.1111/j.1365-2559.2012.04182.x ↗
49. 10.1007/s13277-013-1400-010.1007/s13277-013-1400-0 ↗
50. 10.1158/0008-5472.CAN-14-134910.1158/0008-5472.CAN-14-1349 ↗
51. Dankner M. · OncoImmunology · 2017 · 6
52. 10.1200/JCO.2020.38.15_suppl.309410.1200/JCO.2020.38.15_suppl.3094 ↗
53. 10.1002/advs.20190010110.1002/advs.201900101 ↗
54. 10.2217/nnm-2020-010210.2217/nnm-2020-0102 ↗
55. 10.1371/journal.pone.009447610.1371/journal.pone.0094476 ↗
56. 10.1016/j.cell.2017.07.02510.1016/j.cell.2017.07.025 ↗
57. 10.1038/s41416-020-0763-410.1038/s41416-020-0763-4 ↗
58. 10.3389/fimmu.2015.0033010.3389/fimmu.2015.00330 ↗
59. 10.1038/nmeth.201910.1038/nmeth.2019 ↗